 Researchers are investigating the clinical significance of c @-@ KIT mutations in AML . These are prevalent , and potentially clinically relevant because of the availability of tyrosine kinase inhibitors , such as imatinib and sunitinib that can block the activity of c @-@ KIT pharmacologically . It is expected that additional markers ( e.g. , RUNX1 , ASXL1 , and TP53 ) that have consistently been associated with an inferior outcome will soon be included in these recommendations . The prognostic importance of other mutated genes ( e.g. , DNMT3A , IDH1 , IDH2 ) is less clear . 
 Researchers are investigating the clinical significance of c @-@ KIT mutations in AML . These <a href='drop_aux' title='1'><mark>are</mark></a>prevalent , and potentially clinically relevant because of the availability of tyrosine kinase inhibitors , such as imatinib and sunitinib <a href='null_relcl' title='2'><mark>that</mark></a>can block the activity of c @-@ KIT pharmacologically . It is expected that additional markers ( e.g. , RUNX1 , ASXL1 , and TP53 ) <a href='null_relcl' title='3'><mark>that</mark></a><a href='been_done' title='4'><mark>have</mark></a> consistently been associated with an inferior outcome will soon be included in these recommendations . The prognostic importance of other mutated genes ( e.g. , DNMT3A , IDH1 , IDH2 ) <a href='drop_aux' title='5'><mark>is</mark></a>less clear . 
Researchers are investigating the clinical significance of c @-@ KIT mutations in AML . These prevalent , and potentially clinically relevant b/c of the availability of tyrosine kinase inhibitors , such as imatinib and sunitinib can block the activity of c @-@ KIT pharmacologically . It is expected that additional markers ( e.g. , RUNX1 , ASXL1 , and TP53 ) done consistently been associated wid an inferior outcome will soon b included in these recommendations . The prognostic importance of other mutated genes ( e.g. , DNMT3A , IDH1 , IDH2 ) less clear .